证券代码：603182 证券简称：嘉华股份 公告编号：2025-014 山东嘉华生物科技股份有限公司 关于召开 2024 年度暨 2025 年第一季度业绩暨 现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2025 年 04 月 28 日 （星期一） 至 05 月 07 日 （星期三）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 sinoglory@sinoglorygroup.com 进行提问。公司将在说明会上对投资者普遍关 注的问题进行回答。 山东嘉华生物科技股份有限公司（以下简称"公司"）已于 2025 年 4 月 16 日及 2025 年 4 月 26 日发布公司 2024 年度报告及 2025 年第一季度报告，为便于 广大投资者更全面深入地了解公司 2024 年度及 2025 年第一季度的经营成果、财 务状况，公司计划于 2025 年 05 月 08 日 （星期四） 09:00-10:00 举行 2024 年 度暨 2025 年第一季度业 ...

Financial Performance - The company's revenue for Q1 2025 was CNY 347,563,629.15, a decrease of 11.79% compared to CNY 394,014,949.66 in the same period last year[4] - Net profit attributable to shareholders increased by 14.35% to CNY 35,714,134.90 from CNY 31,232,701.74 year-on-year[4] - Total revenue for Q1 2025 was CNY 347,563,629.15, a decrease of 11.8% compared to CNY 394,014,949.66 in Q1 2024[16] - Net profit for Q1 2025 increased to CNY 35,714,134.90, compared to CNY 31,232,701.74 in Q1 2024, representing a growth of 14.0%[17] - Basic and diluted earnings per share rose by 15.79% to CNY 0.22 from CNY 0.19 in the same period last year[4] - Basic and diluted earnings per share for Q1 2025 were both CNY 0.22, up from CNY 0.19 in Q1 2024[18] Cash Flow - The net cash flow from operating activities was CNY 48,277,455.90, showing a slight increase of 1.39% compared to CNY 47,617,500.35 in the previous year[4] - The company’s cash flow from operating activities showed improvement, contributing positively to the overall financial health[16] - In Q1 2025, the cash inflow from operating activities was CNY 417,455,432.64, slightly down from CNY 419,457,949.95 in Q1 2024, representing a decrease of approximately 0.48%[20] - The net cash flow from operating activities for Q1 2025 was CNY 48,277,455.90, an increase from CNY 47,617,500.35 in Q1 2024, reflecting a growth of about 1.39%[21] - The cash outflow for investing activities in Q1 2025 was CNY 9,206,300.20, significantly lower than CNY 31,446,829.19 in Q1 2024, indicating a reduction of approximately 70.7%[21] - The net cash flow from investing activities for Q1 2025 was -CNY 9,058,128.69, an improvement compared to -CNY 31,446,829.19 in Q1 2024[21] - The cash outflow from financing activities in Q1 2025 was CNY 5,148,166.66, down from CNY 35,139,875.00 in Q1 2024, showing a decrease of about 85.3%[22] - The net increase in cash and cash equivalents for Q1 2025 was CNY 35,735,268.16, contrasting with a decrease of CNY 18,312,209.10 in Q1 2024[22] - The ending balance of cash and cash equivalents as of the end of Q1 2025 was CNY 183,012,749.51, compared to CNY 287,810,482.13 at the end of Q1 2024[22] Assets and Equity - Total assets at the end of Q1 2025 were CNY 1,465,468,000.56, reflecting a 2.33% increase from CNY 1,432,076,811.08 at the end of the previous year[5] - Total equity attributable to shareholders increased to CNY 1,111,255,998.82 from CNY 1,075,317,844.81[14] - Shareholders' equity attributable to the parent company increased by 3.34% to CNY 1,111,255,998.82 from CNY 1,075,317,844.81 at the end of the previous year[5] - Total liabilities amounted to CNY 354,212,001.74, slightly down from CNY 356,758,966.27[14] Research and Development - Research and development expenses for Q1 2025 were CNY 2,505,340.70, compared to CNY 1,617,262.23 in Q1 2024, indicating a significant increase of 54.8%[17] Shareholder Information - The total number of common shareholders at the end of the reporting period was 9,555[8] - The top shareholder, Zhang Guanling, holds 22,372,688 shares, representing 13.60% of the total shares[8] Other Information - Non-recurring gains and losses included government subsidies of CNY 700,000 and other non-operating income of CNY 2,000.00[6] - The company has not disclosed any significant new product developments or market expansion strategies in this report[10]

证券代码：603182 证券简称：嘉华股份 公告编号：2025-003 山东嘉华生物科技股份有限公司 第六届董事会第二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 山东嘉华生物科技股份有限公司（以下简称"公司"）第六届董事会第二次 会议的通知于 2025 年 4 月 3 日以通讯方式发出，会议于 2025 年 4 月 14 日在公 司会议室以现场结合通讯方式召开。会议应出席董事 8 名，实际出席董事 8 名， 董事长李广庆先生主持了本次会议，公司监事及高级管理人员列席会议。会议的 通知、召集、召开和表决程序符合《中华人民共和国公司法》等有关法律、法规 及《公司章程》的规定。 二、董事会会议审议情况 （一）审议通过《关于<2024 年度总经理工作报告>的议案》 表决结果：8 票赞成，0 票反对，0 票弃权。 （二）审议通过《关于<2024 年度董事会工作报告>的议案》 2024 年度，公司董事会严格按照《公司法》《证券法》等法律法规以及《公 司章程》《董事会议事规则》等相关规定，本着对全 ...

Financial Performance - The company's operating revenue for 2024 was CNY 1,488,211,967.24, a decrease of 12.17% compared to CNY 1,694,517,065.04 in 2023[24]. - The net profit attributable to shareholders for 2024 was CNY 109,135,712.73, reflecting a slight decrease of 0.91% from CNY 110,135,183.05 in 2023[24]. - The net cash flow from operating activities significantly increased to CNY 313,810,520.73, a rise of 740.43% compared to CNY 37,339,315.46 in 2023[24]. - The total assets of the company as of the end of 2024 reached CNY 1,432,076,811.08, an increase of 11.45% from CNY 1,284,976,813.31 at the end of 2023[24]. - The net assets attributable to shareholders increased to CNY 1,075,317,844.81, up by 4.49% from CNY 1,029,145,337.06 in 2023[24]. - The basic earnings per share for 2024 was CNY 0.66, a decrease of 1.49% compared to CNY 0.67 in 2023[25]. - The company achieved a weighted average return on equity of 10.43%, down 0.66 percentage points from the previous year[26]. - The gross margin for the main business was 12.27%, down 0.20 percentage points compared to the previous year[61]. - The main business revenue from soybean protein was 889 million RMB, a decrease of 8.03% year-on-year, with a gross margin of 7.07%[61]. - Net profit attributable to shareholders was CNY 109 million, a decrease of 0.91% year-on-year[35]. Dividend Policy - The company plans to distribute a cash dividend of CNY 0.10 per share, totaling CNY 16,455,000.00, which represents 15.08% of the net profit attributable to shareholders[6]. - The company anticipates a mid-term cash dividend in 2025, expected to be no less than 60% of the net profit for that period[7]. - The company declared a cash dividend of CNY 16,455,000, which represents 15.08% of the net profit attributable to ordinary shareholders in the consolidated financial statements[123]. - Over the last three accounting years, the cumulative cash dividend amount (including tax) was CNY 82,275,000, with an average annual net profit of CNY 109,635,447.89, resulting in a cash dividend ratio of 75.04%[124]. Operational Efficiency - The company reported a significant decrease in comprehensive costs while meeting production targets through efficiency improvements[35]. - The company achieved substantial progress in the research and development of soybean protein applications and specialized proteins, with 4 invention patents authorized and 7 new patents filed during the year[38]. - The company reported a significant increase in net cash flow from operating activities, amounting to 314 million RMB, up 740.43% year-on-year[59]. - The production volume of soybean protein increased by 7.35% to 64,970 tons, while sales volume rose by 8.22% to 63,970 tons[63]. - The company has actively engaged in technological innovation and cost reduction measures to enhance operational efficiency[187]. Market and Product Development - The company is actively expanding its product range, including new types of soybean protein products, to meet the growing demand in various sectors such as meat products, dairy, and health foods[42]. - The soybean protein market in China is projected to grow from approximately $1.9 billion in 2021 to $3.5 billion by 2028, with a compound annual growth rate (CAGR) of 9.20%[43]. - The company is focusing on optimizing its organizational structure and enhancing internal control management to achieve long-term high-quality development[39]. - The company is leveraging government policies that support the agricultural and food processing industries, which will help improve product innovation and market expansion[44]. - The company is enhancing customer service and the transformation of research results to improve product quality standards and meet market demands[38]. Risk Management - There were no significant risks impacting the company's operations during the reporting period[10]. - The company faces risks related to food safety, new product development, and intensified market competition[88]. - The company faces risks from fluctuations in the price of non-GMO soybeans, which significantly impact its main business costs[89]. - Environmental risks are present due to waste generation during production, but pollutant emissions have complied with relevant standards without penalties from authorities[89]. Governance and Compliance - The company adheres to legal and regulatory requirements for corporate governance, ensuring efficient operation and decision-making processes[92]. - The company maintains a high level of transparency in information disclosure, ensuring all shareholders receive timely and accurate information[94]. - The company has no controlling shareholder, ensuring independence in operations and management[95]. - The company has implemented measures to manage insider information, with no incidents of leakage or insider trading reported[94]. - The company has established a comprehensive internal control management system, continuously optimizing its governance structure and internal control system based on actual operations[127]. Environmental Responsibility - The company has invested a total of 4.08 million yuan in public welfare projects, including donations to various charitable organizations[140]. - The company has committed 16.00 million yuan towards poverty alleviation and rural revitalization efforts[140]. - The company has installed a new ethanol tail gas activated carbon adsorption recovery device to further reduce waste gas emissions[138]. - The company has not reported any environmental violations or administrative penalties during the reporting period, maintaining compliance with pollution discharge standards[132]. - The company reported a nitrogen oxide emission concentration of 26.3 mg/m³, well below the regulatory limit of 50 mg/m³[133]. Shareholder Structure - The total number of shares held by directors and senior management increased from 34,398,319 to 34,439,319, with a net increase of 41,000 shares[100]. - The total number of common shareholders as of the end of the reporting period is 10,834, an increase from 9,555 at the end of the previous month[195]. - The shareholder structure remains stable with no significant changes in the asset and liability structure reported[195]. - The company has identified consistent action among certain shareholders, indicating a close relationship among them[200]. Strategic Initiatives - The company plans to optimize product structure and expand market share, focusing on differentiated competitive advantages[86]. - The company aims to enhance brand image and quality management as part of its operational strategy for 2025[86]. - The company will actively implement fundraising projects to improve profitability and market competitiveness, aiming for early revenue generation[159]. - The company will strengthen its investment decision-making processes and improve fund utilization efficiency to control costs and financial expenses[159].

本次授信金额：公司及全资子公司拟向银行等金融机构申请总额不超过 人民币 7 亿元的综合授信额度。 审议程序：公司第六届董事会第二次会议审议通过了《关于公司向金融 机构申请综合授信额度的议案》，该议案尚需提交公司股东大会审议。 一、申请授信额度的基本情况 为满足公司经营发展的资金需求，公司及全资子公司拟向银行等金融机构 申请总额不超过人民币7亿元的综合授信额度，授信业务包括但不限于项目贷 款、流动资金贷款、固定资产贷款、银行承兑汇票、银行保函、外币业务、信 用证、贸易融资、进口押汇、进口T/T押汇、进口代付、商票保贴、买断式票据 直贴等，担保方式包括但不限于保证担保、不动产或动产抵押担保、财产权利 质押担保等，具体以金融机构最终核定为准。授信额度不等于公司实际融资金 额，具体融资时间、融资金额及品种将视公司业务发展的实际需求来确定。 证券代码：603182 证券简称：嘉华股份 公告编号：2025-007 山东嘉华生物科技股份有限公司 关于公司向金融机构申请综合授信额度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内 ...

证券代码：603182 证券简称：嘉华股份 公告编号：2025-009 山东嘉华生物科技股份有限公司 关于拟定第六届董事、监事、高级管理人员 薪酬方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 山东嘉华生物科技股份有限公司（以下简称"公司"）于 2025 年 4 月 14 日召开第六届董事会第二次会议及第六届监事会第二次会议，分别审议通过了 《关于拟定第六届董事会董事薪酬方案的议案》《关于拟定第六届高级管理人员 薪酬方案的议案》及《关于拟定第六届监事会监事薪酬方案的议案》，其中在审 议董事薪酬议案时全体董事回避表决，审议监事薪酬议案时全体监事回避表决， 董事会及监事会同意将相关议案直接提交公司股东大会审议。董事会薪酬与考核 委员会认为董事薪酬符合既定方针和章程规定，全体委员回避表决，一致同意提 交董事会审议。审议高级管理人员薪酬议案时，兼任高级管理人员的董事回避表 决。具体情况如下： 一、适用期限 董事、监事的薪酬方案经公司股东大会审议通过后至新的薪酬方案审批通过 之日有效；高级管理人员的薪酬方案经公司董事会审议通 ...

山东嘉华生物科技股份有限公司董事会审计委员会 对会计师事务所 2024 年度履行监督职责情况报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理 准则》《国有企业、上市公司选聘会计师事务所管理办法》《公司章程》《审计 委员会议事规则》等相关规定，山东嘉华生物科技股份有限公司董事会审计委员 会（以下简称"审计委员会"）本着勤勉尽责的原则，认真履行了审计监督职责。 现将审计委员会对天健会计师事务所（特殊普通合伙）（以下简称"天健所"） 2024 年度履行监督职责情况汇报如下： 一、2024 年年审会计师事务所基本情况 | 事务所名称 | 天健会计师事务所（特殊普通合伙） | | | | --- | --- | --- | --- | | 成立日期 | 2011 7 月 18 组织形式 特殊普通合伙 | 年 | 日 | | 注册地址 | 浙江省杭州市西湖区灵隐街道西溪路 128 号 | | | | 首席合伙人 | 钟建国 上年末合伙人数量 241 人 | | | | 上年末执业人 | 注册会计师 2,356 人 | | | | 员数量 | 签署过证券服务业务审计报告的注册会计师 904 人 | ...

山东嘉华生物科技股份有限公司 董事会审计委员会 2024 年度履职情况报告 2024 年度，山东嘉华生物科技股份有限公司（以下简称"公司"）董事会 审计委员会成员根据《上海证券交易所上市公司自律监管指引第 1 号--规范运 作》《公司章程》及《审计委员会议事规则》的有关规定，本着勤勉尽责的原则， 认真履行了审计监督职责。现就 2024 年度工作情况向董事会报告如下： 一、审计委员会的基本情况 公司第五届董事会审计委员会委员由宋云峰先生、王凤荣女士、张效伟先生 担任，由具有会计专业资格的独立董事宋云峰先生担任主任委员。2024 年 12 月 25 日，公司召开 2024 年第一次临时股东大会进行董事会换届选举，选举产生了 第六届董事会董事。同日，公司召开第六届董事会第一次会议，选举独立董事张 章先生、独立董事张辉玉先生、副董事长张效伟先生为公司第六届董事会审计委 员会委员，主任委员由会计专业人士张章先生担任，审计委员会的组成和委员资 格符合相关法律、行政法规、规范性文件及《公司章程》的规定。 二、审计委员会会议召开情况 2024 年度，审计委员会共召开了 6 次会议，全体在任委员均出席了会议， 召开会议的情况具 ...

证券代码：603182 证券简称：嘉华股份 公告编号：2025-010 山东嘉华生物科技股份有限公司 关于开展期货套期保值业务的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 交易目的：为充分利用期货市场的套期保值功能，规避和减少因原材料 价格大幅波动对公司生产经营造成的不利影响，促进公司稳健发展，公司拟使用 部分闲置自有资金开展期货套期保值业务。 交易品种、交易工具、交易场所：公司将在合法合规的期货交易所开展 商品期货套期保值业务，业务包括但不限于期货、期权等合约交易，交易品种主 要是与公司生产经营相关的原材料大豆。 交易金额：公司开展商品期货套期保值业务所需保证金和权利金最高余 额不超过人民币 500.00 万元，该额度在审批期限内可循环滚动使用。 金开展期货套期保值业务。公司将根据生产经营计划择机开展期货套期保值业务， 有效控制市场价格波动风险，保障主营业务稳步发展。 履行的审议程序：公司于 2025 年 4 月 14 日召开第六届董事会第二次会 议，审议通过了《关于开展期货套期保值业务的议案》，该 ...

山东嘉华生物科技股份有限公司 对会计师事务所 2024 年度履职情况评估报告 山东嘉华生物科技股份有限公司（以下简称"公司"）聘请天健会计师事务 所（特殊普通合伙）（以下简称"天健所"）作为公司 2024 年度审计机构。根 据财政部、国资委及证监会颁布的《国有企业、上市公司选聘会计师事务所管理 办法》等法律法规的要求，公司对天健所 2024 年度履职情况进行了评估，具体 情况汇报如下： 一、2024 年年审会计师事务所基本情况 （二）聘任会计师事务所履行的程序 公司于 2024 年 4 月 14 日召开第五届董事会审计委员会第九次会议，审议通 过了《关于续聘会计师事务所的议案》；2024 年 4 月 15 日及 5 月 7 日，公司分 别召开第五届董事会第十四次会议及 2023 年年度股东大会，审议通过了《关于 续聘会计师事务所的议案》，同意继续聘任天健所为公司 2024 年度审计机构。 事务所名称 天健会计师事务所（特殊普通合伙） 成立日期 2011 年 7 月 18 日 组织形式 特殊普通合伙 注册地址 浙江省杭州市西湖区灵隐街道西溪路 128 号 首席合伙人 钟建国 上年末合伙人数量 241 人 上年末 ...